Sign In
Buy SVA
$6.47
+0 (+0%)
At Close: Feb 07, 2020
HONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the �
SINOVAC Board of Directors Prevails Against Advantech/Prime's New York Lawsuit
10:56pm, Friday, 20'th Jun 2025
BEIJING--(BUSINESS WIRE)--SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it has prevailed against A
SINOVAC Board of Directors Files Definitive Proxy Materials
02:18pm, Wednesday, 18'th Jun 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
SINOVAC Announces New Board Member
04:38am, Wednesday, 18'th Jun 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resigna
SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders
01:52pm, Tuesday, 17'th Jun 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
Prime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech's Current Board
07:35pm, Monday, 16'th Jun 2025
HONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the �
BEIJING--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15%
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today disclosed
Prime Success Responds to Sinovac Biotech's False and Misleading Claims
12:00am, Saturday, 14'th Jun 2025
HONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the �
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file it
Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading Claims
08:30am, Wednesday, 11'th Jun 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in S
Prime Success Sends Letter to Sinovac Biotech Shareholders
07:00pm, Tuesday, 10'th Jun 2025
HONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the �
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report
10:00pm, Thursday, 22'nd May 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notific
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend
02:00am, Wednesday, 30'th Apr 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital
03:29am, Tuesday, 29'th Apr 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of director
